Photo from Cesar Perez/LinkedIn
Jan 28, 2025, 09:11
Cesar Perez: Preliminary Phase 2 data for vilastobart in combination with atezolizumab for advanced MSS CRC
Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared on LinkedIn:
“We presented the Preliminary Phase 2 data for vilastobart (XTX101), a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab in patients with advanced MSS CRC
– 40 patients with MSS CRC enrolled in ongoing Phase 2
– 18 response-evaluable patients with at least 1 scan reported
– Low incidence of immune colitis (5%)
– 3 of 11 patients without liver metastatic disease had partial response (27%)
To be continued …”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 13:05